Other News

LivaNova Presents New Data at European Association for Cardio-Thoracic Surgery Annual Meeting Demonstrating Benefits of Perceval Sutureless Valve

New PERSIST-AVR study results and SURE-AVR registry data analysis underscore utility of Perceval as a minimally invasive surgical approach for patients with aortic valve stenosis LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced new data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study and […]

Zynex Announces 96% Year over Year Order Growth

ENGLEWOOD, Co., Oct. 12, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders for Q3 2020. Thomas Sandgaard, CEO of Zynex said: “Similar to most companies we have seen the impact […]

Enrolment of First Two Patients in PRISTINE Study with SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, Oct. 11, 2020 /PRNewswire/ — MedAlliance has announced enrolment of the first two patients in the PRISTINE registry with SELUTION SLR™ 018 DEB for the treatment of patients with Below The Knee disease (Chronic Limb Threatening Ischemia). This is the first DEB accepted by the FDA for its “Breakthrough Program”. SELUTION […]

SpectraWAVE Appoints Eman Namati, Ph.D., as Chief Executive Officer to Lead Development and Launch of Flagship Technology

New Imaging Technology to Improve Coronary Artery Disease Patient Outcomes BEDFORD, Mass., Oct. 9, 2020 /PRNewswire/ — SpectraWAVE, Inc., a development-stage medical imaging company focused on improving coronary artery disease (CAD) outcomes with photonics, is pleased to announce that Eman Namati, Ph.D., has been appointed Chief Executive Officer. Dr. Namati brings more than a […]

Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference

Satera™ Ablation System demonstrates success as a frontline treatment of heart failure NEW YORK, Oct. 9, 2020 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing one of the root causes of heart failure, today announced positive interim results from their first-in-human (FIH) trial of splanchnic ablation for volume management, or […]

Avail Medsystems Raises $100 Million in Series B Funding Led by D1 Capital to Meet Demand for Procedural Telemedicine™ Technology for the Operating Room

Avail has designed the only end-to-end system that helps surgical teams in operating rooms collaborate with remote medical experts for live procedures and clinical training PALO ALTO, Calif.–(BUSINESS WIRE)–Avail Medsystems, the medical technology company pioneering telemedicine for the procedure room (“Procedural TelemedicineTM”), today announced that it has raised $100 million […]

Reflow Medical Receives Approval in Japan for the Wingman Catheter to Cross Chronic Total Occlusions (CTOs) in Peripheral Artery Disease

SAN CLEMENTE, CA /October 7, 2020 /Business Wire/ — Reflow Medical, Inc., a California- based medical device company, announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved the Wingman™ CTO Catheter. Reflow Medical has partnered with Century Medical, Inc. (CMI), a leading medical device distributor based in Tokyo, […]

TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients

DANVERS, Mass.–(BUSINESS WIRE)–The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients will be highlighted at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. […]

NILEMDO® significantly lowers cholesterol in people with familial hypercholesterolaemia shows new analysis presented at EAS 2020

NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol and can be combined with other treatments to help lower cholesterol even further1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to […]